Zeda announced its acquisition of The Orthopaedic Implant Company (OIC), a leader in value-based implants.
Under the terms of the acquisition, OIC will operate worldwide as a Zeda Health company.
OIC’s expertise in value-based implants has set industry benchmarks in the US, making it a pioneer in delivering cost-effective orthopedic devices. The acquisition enables Zeda to produce OIC’s time-tested implant designs, fortifying its mission to provide accessible trauma implants to patients on a worldwide scale.
Commenting on the acquisition, Shri Shetty, CEO of Zeda, said, “The acquisition of OIC represents a pivotal moment for Zeda. Its leadership in value-based implants perfectly complements our additive manufacturing technologies that can deliver high quality orthopedic devices and implants that are accessible to all patients, regardless of country and socioeconomic status. Together, our strengths and expertise will raise the standard of care globally and equitably for the world’s entire population.”
Itai Nemovicher, CEO and Co-Founder of The Orthopaedic Implant Company, commented, “We are proud to join forces with Zeda, a company that shares in our values and dedication to advancing access to critical orthopedic care because it can and should be done. Under Zeda, OIC will reach new heights in providing cost-effective, high-quality orthopedic solutions in the US and abroad.”
Zeda announced its acquisition of The Orthopaedic Implant Company (OIC), a leader in value-based implants.
Under the terms of the acquisition, OIC will operate worldwide as a Zeda Health company.
OIC’s expertise in value-based implants has set industry benchmarks in the US, making it a pioneer in delivering cost-effective orthopedic...
Zeda announced its acquisition of The Orthopaedic Implant Company (OIC), a leader in value-based implants.
Under the terms of the acquisition, OIC will operate worldwide as a Zeda Health company.
OIC’s expertise in value-based implants has set industry benchmarks in the US, making it a pioneer in delivering cost-effective orthopedic devices. The acquisition enables Zeda to produce OIC’s time-tested implant designs, fortifying its mission to provide accessible trauma implants to patients on a worldwide scale.
Commenting on the acquisition, Shri Shetty, CEO of Zeda, said, “The acquisition of OIC represents a pivotal moment for Zeda. Its leadership in value-based implants perfectly complements our additive manufacturing technologies that can deliver high quality orthopedic devices and implants that are accessible to all patients, regardless of country and socioeconomic status. Together, our strengths and expertise will raise the standard of care globally and equitably for the world’s entire population.”
Itai Nemovicher, CEO and Co-Founder of The Orthopaedic Implant Company, commented, “We are proud to join forces with Zeda, a company that shares in our values and dedication to advancing access to critical orthopedic care because it can and should be done. Under Zeda, OIC will reach new heights in providing cost-effective, high-quality orthopedic solutions in the US and abroad.”
Copy to clipboard 
